Trial
NCT04976127
Safety Evaluation of Intravenous Talineuren (TLN) in Parkinson's Disease-affected Patients
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
InnoMedica Schweiz AG
Collaborators
—
Condition
Parkinson Disease
Intervention
Talineuren
Why stopped
Treatment stopped earlier due to Verfügung Swissmedic. Safety visits in the end of the trial still were carried out (LPLV 06.08.2025).
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-04-22